Developmental and pharmacological regulation of apolipoprotein C-II gene expression: Comparison with Apo C-I and Apo C-III gene regulation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 1, 1999, Pages 115-121

  Andersson, Yvonne ^a   Majd, Zouher ^a   Lefebvre, Anne Marie ^a   Martin, Geneviève ^a   Sechkin, Alexander V ^c   Kosykh, Vladimir ^b   Fruchart, Jean Charles ^a   Najib, Jamila ^a   Staels, Bart ^a,d  

^a INSERM   (France)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c Moscow Coordinating Centre of Organ Donation   (Russian Federation)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoproteins; Gene regulation; Hypertriglyceridemia; Hypolipidemic drugs; Lipoprotein metabolism

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; MESSENGER RNA;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL LIVER LEVEL; DRUG EFFECT; DRUG TARGETING; GENE EXPRESSION REGULATION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPOLYSIS; LIPOPROTEIN SYNTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032944440     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.1.115     Document Type: Article

References (51)

1. Fojo SS. Genetic dyslipoproteinemias: role of lipoprotein lipase and apolipoprotein C-II. Curr Opin Lipidol. 1992;3:186-195.
2. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein Lipase From Milk: The Model Enzyme in Lipoprotein Lipase Research. Chicago, Ill: Evener Publishers; 1987:15-58.
3. Myclebost O, Williamson B, Markham AF, Myclebost SR, Rogers J, Woods DE, Humphries SE. The isolation and characterization of cDNA clones for human apolipoprotein CII. J Biol Chem. 1984;259:4401-4404.
4. Zannis VI, Cole FS, Jackson CL, Kurnit DM, Karathanasis SK. Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues: time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry. 1985;24:4450-4455.
5. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med. 1978;298:1265-1273.
6. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hypertriglyceridemia. Metabolism. 1979;28: 1001-1010.
7. Ishibashi S, Murase T, Takahashi K, Mori N, Kawakami M, Takaku F. Plasma apolipoprotein CII levels in hypertriglyceridemia. Metabolism. 1986;35:781-785.
8. Le N-L. Gibson JC, Ginsberg HN. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988;29:669-677.
9. Wang C-S, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
10. Shachter NS, Ebara T, Ramakrishnan R, Steiner G, Breslow JL, Ginsberg HN. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein CI. J Clin Invest. 1996;98:846-855.
11. Jong MC, Dahlmans VEH, van Gorp PJJ, van Dijk KW, Breuer ML, Hofker MH, Havekes LM. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996;98:2259-2267.
12. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Ginsberg IJ, Breslow JL. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994;93:1683-1690.
13. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science. 1990;249:790-793.
14. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:22453-22459.
15. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556-565.
16. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265: 10771-10779.
17. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol. Chem. 1991;266:18259-18267.
18. McConathy WJ, Gesquiere JC, Tartar HBA, Fruchart J-C, Wang C-S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 1992;33:995-1003.
19. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest. 1973;52:32-38.
20. Matsuoka N, Shiai K, Johnson JD, Kashyap ML, Srivastava LS, Yamamura T, Yamamoto A, Saito Y, Kumagai A, Jackson RL. Effects of apolipoprotein C-II (apo C-II) on the lipolysis of very low density and high density lipoproteins from apoC-II deficient patients. Metabolism. 1981;30:818-824.
21. Carlson LA, Ballantyne D. Changing relative proportions of apolipoprotein C-II and C-III of very low density lipoproteins in hypertriglyceridemia. Atherosclerosis. 1976;23:563-568.
22. Erkelens DW, Brunzell JD, Bierman EL. Availability of apolipoprotein CII in relation to the maximal removal capacity for an infused triglyceride emulsion in man. Metabolism. 1979;28:495-501.
23. Staels B, Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharm Des. 1997;3:1-14.
24. Schoonjans K, Staels B, Auwerx J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.
25. Staels B, Auwerx J. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and α-fetoprotein as models. Development. 1992;115:1035-1043.
26. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart J-C, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest. 1995;95:705-712.
27. Staels B, van Tol A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb. 1992;12:286-294.
28. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953-12956.
29. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman R, Briggs M, Deeb S, Staels B. Auwerx J. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-5348.
30. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 1996;384:39-43.
31. Peinado-Onsurbe J, Staels B, Deeb S, Ramirez I, Llobera M, Auwerx J. Neonatal extinction of liver lipoprotein lipase expression. Biochim Biophys Acta. 1992;1131:281-286.
32. Andersson Y, Thelander L, Bengtsson-Olivecrona G. Demonstration of apolipoprotein CII in guinea pigs. J Biol Chem. 1991;266:4074-4080.
33. Andersson Y, Thelander L, Bengtsson-Olivecrona G. Rat apolipoprotein C-II lacks the conserved site for proteolytic cleavage of the pro-form. J Lipid Res. 1991;32:1805-1809.
34. Hoffer MJV, van Eck MM, Havekes LM, Hofker MH, Frants RR. The mouse apolipoprotein C1 gene: structure and expression. Genomics. 1993;18:37-42.
35. Masiakowski P, Breathnach R, Bloch J, Cannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982;10:7895-7903.
36. Scanu AM, Edelstein CE. Solubility in aqueous solutions of ethanol of the small molecular weight peptides of the serum very low density and high density lipoproteins. Anal Biochem. 1971;44:576-588.
37. Mezdour H, Clavey V, Kora I, Koffigan M, Barkia A, Fruchart JC. Anion exchange fast protein chromatography characterization and purification of apolipoproteins AI, AII, CI, CII, CIII0, CIII1, CIII2, and E from human plasma. J Chromatogr. 1987;414:35-45.
38. Bury J, Michiels G, Rosseneu M. Human apolipoprotein CII quantification by sandwich enzyme-linked immunosorbent assay. J Clin Chem Clin Biochem. 1986;24:457-463.
39. Girard J, Perdereau D, Foufelle F, Prip-Buus C, Ferré P. Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J. 1994;8:36-42.
40. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart J-C. Fievet C, Auwerx J, Staels B. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol. 1997;17:1756-1764.
41. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med. 1978;299:1421-1424.
42. Singh-Bist A, Komaromy MC, Kramer FB. Transcriptional regulation of lipoprotein lipase in the heart during development in rat. Biochem Biophys Res Commun. 1994;202:838-843.
43. Vu-Dac N, Schoonjans K, Laine B, Fruchart J-C, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994;269: 31012-31018.
44. Vu-Dac N, Schoonjans K, Kosykh V, Dallongville J, Fruchart J-C, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96:741-750.
45. Larsen ML, Illingworth DR. Triglyceride-lowering agents: fibrates and nicotinic acid. Curr Opin Lipidol. 1993;4:34-40.
46. Schoonjans K, Staels B, Grimaldi P, Auwerx J. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem. 1993;216:615-622.
47. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III. J Biol Chem. 1995;270:13470-13475.
48. Yang C-Y, Gu Z-W, Xie Y-H, Valentinova NV, Yang M, Yeshurun D, Quion JAV, Gotto AM Jr. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Atherosclerosis. 1996; 126:105-116.
49. Lussier-Cacan S, Bard J-M, Boulet L, Nestruck AC, Grothé A-M, Fruchart J-C, Davignon J. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis. 1989;78: 167-182.
50. Windler E, Chao Y-S, Havel RJ. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. J Biol Chem. 1980;255: 8303-8307.
51. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75: 1702-1712.